<?xml version="1.0" encoding="UTF-8"?><html xmlns="http://www.w3.org/1999/xhtml" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:protege="http://protege.stanford.edu/plugins/owl/protege#" xmlns:xsp="http://www.owl-ontologies.com/2005/08/07/xsp.owl#" xmlns:Thesaurus="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:dublincorens="http://purl.org/dc/elements/1.1/"  version="XHTML+RDFa 1.0" ><body>RALP1 Is Rhoptry Neck Erythrocyte-Binding Protein Plasmodium <br /> falciparum Merozoites Potential Blood-Stage Vaccine Candidate <br /> Antigen <br /> Daisuke Ito,a Tomoyuki Hasegawa,a Kazutoyo Miura,b Tsutomu Yamasaki,a* Thangavelu U. Arumugam,a Amporn Thongkukiatkul,c <br /> Satoru Takeo,a* Eizo Takashima,a Jetsumon Sattabongkot,d Eun-Taek Han,e Carole A. Long,b Motomi Torii,f Takafumi Tsuboia,g <br /> Division Malaria Research, Proteo-Science Center,a Venture Business Laboratory,g Ehime University, Matsuyama, Ehime, Japan; Laboratory Malaria Vector <br /> Research, National Institute Allergy Infectious Diseases, National Institutes Health, Rockville, Maryland, USAb; Department Biology, Faculty Science, Burapha <br /> University, Chonburi, Thailandc; Mahidol Vivax Research <span id='am-1' about='Thesaurus:Unit' typeof='owl:Thing'>Unit</span>, Faculty Tropical Medicine, Mahidol University, Bangkok, Thailandd; Department Medical Environmental <br /> Biology Tropical Medicine, School Medicine, Kangwon National University, Chuncheon, Gangwon-do, Republic Koreae; Division Molecular Parasitology, <br /> Proteo-Science Center, Ehime University, Shitsukawa, Toon, Ehime, Japanf <br />  <br /> Erythrocyte invasion merozoites obligatory stage Plasmodium infection essential disease progression. Pro- <br /> teins apical organelles merozoites mediate invasion erythrocytes potential malaria vaccine candidates. <br /> Rhoptry-associated, leucine zipper-like protein 1 (RALP1) Plasmodium falciparum previously specifically <br /> expressed schizont stages localized rhoptries merozoites immunofluorescence assay (IFA). Also, RALP1 has <br /> been refractory gene <span id='am-84' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-85' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-86' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-87' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-88' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-89' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-90' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-91' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-92' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-93' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-94' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-95' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-96' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-97' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-98' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-99' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-100' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-101' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-102' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-103' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-104' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-105' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-106' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-107' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-108' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-109' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-110' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-111' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-112' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-113' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-114' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-115' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-116' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-117' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-118' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-119' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-120' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-121' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-122' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-123' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-124' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-125' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-126' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-127' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-128' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-129' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-130' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-131' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-132' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-133' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-134' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-135' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-136' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-137' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-138' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-139' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-140' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-141' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-142' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-143' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-144' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-145' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-146' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-147' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-148' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-149' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-150' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-151' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-152' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-153' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-154' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-155' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-156' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-157' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-158' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-159' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-160' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-161' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span>knockout</span> attempts, suggesting essential blood-stage parasite <span id='am-6' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-7' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-8' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-9' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-10' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-11' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-12' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-13' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-14' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-15' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-16' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-17' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-18' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-19' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-20' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-21' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-22' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-23' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-24' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-25' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-26' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-27' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-28' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-29' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-30' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-31' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-32' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-33' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-34' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-35' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-36' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-37' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-38' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-39' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-40' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-41' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-42' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-43' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-44' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-45' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-46' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-47' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-48' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-49' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-50' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-51' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-52' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-53' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-54' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-55' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-56' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-57' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-58' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-59' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-60' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-61' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-62' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-63' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-64' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-65' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-66' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-67' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-68' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-69' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-70' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-71' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-72' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-73' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-74' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-75' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-76' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-77' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-78' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-79' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-80' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-81' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-82' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-83' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span>survival</span>. These characteristics <br /> suggest RALP1 potential blood-stage vaccine candidate antigen, assessed potential regard. <br /> Antibodies raised recombinant RALP1 proteins synthesized using wheat germ cell-free system. Immunoelec- <br /> tron microscopy demonstrated time RALP1 rhoptry neck protein merozoites. Moreover, IFA data <br /> showed RALP1 translocates rhoptry neck moving junction merozoite invasion. Growth invasion <br /> inhibition assays revealed anti-RALP1 antibodies inhibit invasion erythrocytes merozoites. The findings that <br /> RALP1 possesses erythrocyte-binding epitope C-terminal region anti-RALP1 antibodies disrupt tight-junction <br /> formation, evidence RALP1 plays important role merozoite invasion erythrocytes. In addition, human sera <br /> collected areas Thailand Mali malaria endemic recognized protein. Overall, findings indicate that <br /> RALP1 rhoptry neck erythrocyte-binding protein qualifies potential blood-stage vaccine candidate. <br />  <br />  <br />  <br />  <br /> P   lasmodium falciparum virulent malaria parasite of <br />     species infecting humans, affecting 216 million <br /> individuals killing 0.7 million individuals 2010 <br />                                                                                         parasitophorous vacuole (PV). After attachment merozoites <span id='am-5' about='protege:TO' typeof='owl:Thing'>to</span> <br />                                                                                         erythrocytes, rhoptry proteins mediate direct high-affinity mero- <br />                                                                                         zoite-erythrocyte interactions micronemal proteins (7) that <br /> worldwide (1). Since half 1950s, appearance                    ultimately lead tight-junction formation irreversible com- <br /> malaria parasites resistance antimalarial drugs mos-                     mitment merozoite invasion. The tight junction char- <br /> quito vectors resistance insecticides highlighted                       acterized electron-dense thickening erythrocyte <br /> importance malaria vaccine development. Although number                            membrane merozoite, molecular makeup yet <br /> of vaccine candidates developed tested preclini-                       fully understood, known include number of <br /> cal clinical trials, limited clinical success                         rhoptry neck proteins (RONs), micronemal protein <br /> achieved vaccines date (2, 3). Therefore, discovery novel                    AMA1 (8, 9). On hand, proteins belonging the <br /> vaccine candidates currently important step                        reticulocyte-binding-like homologue (Rh) protein family, located <br /> renewed focus control, local elimination, eventual global                        rhoptries, shown translocate bind eryth- <br /> eradication efforts (4). <br />     The symptoms malaria caused blood-stage cyclic in- <br /> fection subsequent rupture host&#226;&#8364;&#8482;s erythrocytes obli-                          Received 1 June 2013 Returned modification 10 July 2013 <br />                                                                                             Accepted 29 August 2013 <br /> gate asexual intracellular malaria parasites. Erythrocyte invasion <br />                                                                                             Published ahead print 3 September 2013 <br /> by merozoite, invasive form blood-stage parasite <br />                                                                                             Editor: J. H. Adams <br /> exposed human immunity, mediated complex set of <br />                                                                                             Address correspondence Takafumi Tsuboi, tsuboi@ccr.ehime-u.ac.jp. <br /> interactions different parasite ligands erythrocyte re- <br />                                                                                             * Present address: Tsutomu Yamasaki, Department Life Science, Faculty of <br /> ceptors (5&#226;&#8364;&#8220;7). The ligands used merozoite invasion <br />                                                                                             Science, Okayama University Science, Okayama, Japan; Satoru Takeo, Division of <br /> are expressed surface merozoite discharged                          Tropical Diseases Parasitology, Department Infectious Diseases, Faculty of <br /> <span id='am-3' about='protege:FROM' typeof='owl:Thing'>from</span> specialized apical organelles (rhoptries, micronemes,                              Medicine, Kyorin University, Mitaka, Tokyo, Japan. <br /> dense granules) (5&#226;&#8364;&#8220;7). Among apical organelles, rhoptries                           Supplemental material article http://dx.doi.org/10.1128 <br /> the prominent large secretory organelles present pairs                           /IAI.00690-13. <br /> the apical tip merozoite contents thought                        Copyright &#194;&#169; 2013, American Society Microbiology. All Rights Reserved. <br /> important invasion processes, initial host                           doi:10.1128/IAI.00690-13 <br /> cell sensing, tight-junction formation, establishment the <br />  <br />  <br /> 4290   iai.asm.org                                    Infection Immunity    p. 4290 &#226;&#8364;&#8220; 4298                                      November 2013 Volume 81 Number 11 <br />                                                                                                      P. falciparum RALP1, Potential Malaria Vaccine Candidate <br />  <br />  <br />  <br /> rocytes, leading tight-junction formation, play di-             region RALP1, encompassing 396 aa [F17 Q412]), RALP1-C1 (C- <br /> rect role invasion (10). In way, rhoptry proteins                terminal region RALP1, encompassing 239 aa [N396 P634]), and <br /> represent promising blood-stage P. falciparum vaccine candidates.              RALP1-C2 (C-terminal region RALP1, encompassing 315 aa [N396 to <br /> Therefore, study taken objective character-            K710]) amplified P. falciparum 3D7 genomic DNA PCR by <br /> izing P. falciparum rhoptry proteins assessing novel               using sense primers XhoI sites antisense primers BamHI <br /> blood-stage vaccine candidates.                                                restriction sites (in lowercase letters primer sequences below). <br />     Previous bioinformatic searches using transcriptional                  Primers RALP1-N1-F (5=-ctcgagATGCCACTTCAACGTGGCGCATC- <br />                                                                                3=) RALP1-N1-R (5=-ggatccCTAGTGATGATGATGATGATGATCA <br /> structural features known proteins Haase et al. (11) have <br />                                                                                ACGTTCACATTCATTTGTTGATT-3=), primers RALP1-N2-F (5=-ctcga <br /> identified hypothetical proteins probably located on <br />                                                                                gTTTTACCTGATAAAGTCATCTTCCAAT-3=) RALP1-N2-R (5=-g <br /> the surface merozoite secretory organelles. Of                gatccCTATTGATCATTCATCAATTTTACAAAAAC-3=), primers <br /> these candidates, experimentally shown                        RALP1-C1-F (5=-ctcgagAATGGTAAGAAGGATAAAAATGGGGT-3=) <br /> PF3D7_0722200 appears localized rhoptry P.                     RALP1-C1-R (5=-ggatccCTATGGTACATTTTTAGGTGTAAAAGT <br /> falciparum merozoites possess leucine zipper-like do-                 AGT-3=), primers RALP1-C2-F (5=-ctcgagAATGGTAAGAAGGATA <br /> main, structural feature facilitates protein-protein inter-             AAAATGGGGT-3=) RALP1-C2-R (5=-ggatccCTATTTGTTTCCCA <br /> action, designated rhoptry-associated leucine zip-                TATCATTTTTATTATATTT-3=) used generate DNA <br /> per-like protein 1 (RALP1). Furthermore, RALP1 conserved                 fragments encoding RALP1-N1, -N2, -C1, -C2 proteins, respec- <br /> Plasmodium spp. refractory <span id='am-162' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-163' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-164' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-165' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-166' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-167' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-168' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-169' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-170' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-171' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-172' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-173' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-174' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-175' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-176' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-177' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-178' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-179' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-180' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-181' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-182' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-183' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-184' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-185' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-186' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-187' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-188' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-189' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-190' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-191' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-192' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-193' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-194' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-195' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-196' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-197' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-198' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-199' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-200' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-201' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-202' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-203' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-204' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-205' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-206' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-207' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-208' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-209' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-210' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-211' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-212' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-213' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-214' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-215' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-216' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-217' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-218' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-219' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-220' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-221' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-222' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-223' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-224' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-225' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-226' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-227' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-228' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-229' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-230' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-231' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-232' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-233' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-234' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-235' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-236' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-237' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-238' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-239' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span>gene knockout</span> attempts (11),           tively. The underlined sequences primer RALP1-N1-R indicate re- <br /> suggesting RALP1 play important role invasion.                gions encode hexahistidine tag. <br /> However, far, studies attempted growth and/or invasion                  The amplified fragments restricted ligated the <br /> inhibition assays antibodies raised recombinant RALP1             wheat germ cell-free expression vectors (CellFree Sciences). The fragment <br /> proteins; therefore, RALP1 characterized vaccine            encoding RALP1-N1 cloned pEU-E01-MCS vector. Frag- <br /> candidate. In study, attempted test RALP1              ments encoding RALP1-N2, -C1, -C2 cloned pEU-E01- <br />                                                                                GST-TEV-N2 vector. The cloned inserts sequenced ABI <br /> potential blood-stage vaccine candidate. In regard, expressed <br />                                                                                PRISM 3100-Avant genetic analyzer (Applied Biosystems, Foster City, <br /> recombinant RALP1 using wheat germ cell-free system, de-                CA). The recombinant proteins His glutathione S-trans- <br /> fined subcellular localization RALP1 immunoelectron mi-              ferase (GST) tag expressed wheat germ cell-free and <br /> croscopy (IEM), tested growth and/or invasion inhibition activity          purified nickel-Sepharose column (GE Healthcare) the <br /> of anti-RALP1 antibodies, analyzed reactivity malaria im-           case RALP1-C1 glutathione-Sepharose 4B column (GE Health- <br /> mune human sera RALP1.                                                      care). GST-tagged RALP1-N2 purified glutathione elution. In the <br />                                                                                case GST-tagged RALP1-C1 -C2 proteins, N-terminal GST <br /> MATERIALS AND METHODS                                                          tag removed eluting GST-tagged RALP1 bound glutathione- <br /> Parasite culture free-merozoite purification. P. falciparum asexual        Sepharose 4B column using tobacco etch virus (TEV) protease, which <br /> stages (strain 3D7A National Institute Allergy Infectious      cleaves TEV recognition site GST tag RALP1 <br /> Diseases [NIAID], NIH) maintained vitro erythrocytes           fragment. All detailed methods used wheat germ cell-free pro- <br /> healthy human donors (blood group O&#226;&#171;&#185;) obtained Japanese Red           tein synthesis affinity purification described previously (16). <br /> Cross Society described (12). To harvest parasite pellets, ma-        To generate antisera protein (RALP1-N1, -C1, -C2), <br /> ture schizonts purified differential centrifugation 70%/40%       BALB/c mice immunized subcutaneously 20 &#226;?&#174;g purified <br /> Percoll-sorbitol gradient treated tetanolysin (List Biolog-   recombinant protein emulsified Freund&#226;&#8364;&#8482;s complete adjuvant, fol- <br /> ical Laboratories, Inc., Campbell, CA) remove hemoglobin loss       lowed 20 &#226;?&#174;g protein Freund&#226;&#8364;&#8482;s incomplete adjuvant. A <br /> of parasite proteins present PV space (13), washed phosphate-      Japanese white rabbit immunized subcutaneously 250 &#226;?&#174;g of <br /> buffered saline (PBS) containing Complete protease inhibitor (Roche,           purified protein Freund&#226;&#8364;&#8482;s complete adjuvant, followed 250 &#226;?&#174;g of <br /> Mannheim, Germany), stored &#226;&#171;&#186;80&#194;&#176;C used. The viable free            purified protein Freund&#226;&#8364;&#8482;s incomplete adjuvant. All immunizations <br /> merozoites retain invasive capacity purified basis   times 3-week intervals, antisera collected <br /> the recently reported protocol (14). Briefly, parasites synchronized <br />                                                                                14 days immunization. All animal experimental pro- <br /> by using sorbitol treatment heparin (Mochida Pharmaceutical Co., <br />                                                                                tocols approved Institutional Animal Care Use Commit- <br /> Tokyo, Japan). Late-stage parasites (32 36 h postinvasion) purified <br />                                                                                tee Ehime University (su-14-6), experiments conducted <br /> (&#226;&#172;&#381;95% purity) magnetic separation MACS CS column con- <br />                                                                                according Ethical Guidelines Animal Experiments Ehime <br /> junction VarioMACS magnetic separator (Miltenyi Biotec, Cam- <br />                                                                                University. In similar manner, mouse anti-RAP1 (M1 D782 3D7 <br /> bridge, MA), incubated 10 &#226;?&#174;M E64 (Sigma-Aldrich Corporation, St. <br /> Louis, MO) 6 8 h, pelleted. Resulting E64-treated schizonts    sequence [PF3D7_1410400]) antibody, mouse rabbit anti-AMA1 <br /> resuspended small volume incomplete culture medium (contain-           (Q25 K546 3D7 sequence [PF3D7_1133400]) antibodies, and <br /> ing protein component) filtered 1.2-&#226;?&#174;m Acrodisc               rabbit anti-GST antibody generated previously described (17). <br /> 32-mm syringe filter (Pall Corporation, Port Washington, NY).                  Mouse anti-RON4 monoclonal antibody (26C64F12) (8) kind gift <br />     Production recombinant proteins antisera. Genomic DNA               Jean F. Dubremetz (Universit&#195;&#169; Montpellier 2, Montpellier, <br /> was extracted P. falciparum strain 3D7A DNAzol reagent           France). <br /> (Invitrogen, Carlsbad, CA). The nucleotide sequence ralp1 gene              In order obtain antigen-specific IgGs, rabbit antisera RALP1 <br /> (PF3D7_0722200) strain 3D7 obtained malaria genome             proteins affinity purified columns conjugated respective <br /> database PlasmoDB (http://plasmodb.org). In order generate specific         recombinant RALP1 proteins ligands. Briefly, recombinant RALP1 <br /> antibodies, truncated regions ralp1 gene amplified ex-         proteins covalently linked HiTrap NHS-Activated HP columns <br /> pressed recombinant proteins wheat germ cell-free translation      (GE Healthcare) accordance manufacturer&#226;&#8364;&#8482;s recommenda- <br /> system (CellFree Sciences, Matsuyama, Japan) described previously           tions. Rabbit antisera applied RALP1 protein-conjugated <br /> (15). Briefly, PF3D7_0722200 fragments encoding RALP1-N1 (N-               column. After extensive washing 20 mM phosphate buffer (pH 7.0), <br /> terminal region RALP1, encompassing 114 amino acids [aa; M35             antigen-specific IgGs eluted 0.1 M glycine-HCl, pH 2.5, and <br /> D148] hexahistidine tag C terminus), RALP1-N2 (N-terminal         immediately neutralized 1 M Tris, pH 9.0. <br />  <br />  <br /> November 2013 Volume 81 Number 11                                                                                                           iai.asm.org 4291 <br />  Ito et al. <br />  <br />  <br />  <br />      Preparation parasite schizont extract Western blot analysis.       flow cytometry described previously (19). Briefly, parasite cultures <br /> Purified, schizont-rich parasite pellets lysed appropriate          synchronized day start GIA, majority <br /> amount reducing SDS-PAGE sample buffer incubated 98&#194;&#176;C           parasites late trophozoite-to-schizont stage start the <br /> for 3 min. The lysate centrifuged 10,000 &#226;&#171;&#187; g 10 min room         GIA. Twenty microliters parasite-infected erythrocyte (pRBC) suspen- <br /> temperature (RT), supernatants subjected electrophoresis        sion (0.3% parasitemia 2% hematocrit) 20 &#226;?&#174;l IgGs added <br /> a 12.5% polyacrylamide gel (ATTO, Tokyo, Japan). Proteins            half-area flat-bottom 96-well cell culture microplates (Corn- <br /> transferred 0.2-&#226;?&#174;m polyvinylidene difluoride membrane (Hybond             ing, Corning, NY) gently mixed. For control, 20 &#226;?&#174;l culture me- <br /> LFP; GE Healthcare) semidry blotting (ATTO). The mem-            dium added pRBC suspension. Cultures incubated 37&#194;&#176;C <br /> branes blocked PBS-MT (PBS containing 5% [wt/vol] nonfat             humidified, gassed (90% N2, 5% O2, 5% CO2), airtight boxes. After <br /> milk 0.1% [vol/vol] Tween 20), lanes cut strips. Then        25 h incubation, invading parasites developed to <br /> each membrane strip immunostained antiserum RT 1          early trophozoite stage, pRBC pelleted brief centrifugation <br /> h, followed horseradish peroxidase-conjugated secondary-antibody            (1,300 &#226;&#171;&#187; g 5 min) washed 100 &#226;?&#174;l PBS. The cells then <br /> (GE Healthcare) probing, visualized Immobilon Western                 incubated 50 &#226;?&#174;l diluted (1:1,000 PBS) SYBR green I (Invitro- <br /> chemiluminescent horseradish peroxidase substrate (Millipore, Billerica,       gen) 10 min RT washed PBS. Parasitemia measured <br /> MA) LAS 4000 Mini luminescent-image analyzer (GE Healthcare).             flow cytometry FACSCanto II (BD Biosciences, San Jose, CA) by <br /> The relative molecular masses proteins estimated refer-       acquisition 50,000 events sample. Data analyzed with <br /> ence Precision Plus protein standards (Bio-Rad, Hercules, CA).              FlowJo 9.1 software (Tree Star, Ashley, OR) gating intact eryth- <br />      Imaging schizont merozoite invasion indirect immuno-            rocytes scatter forward scatter parameters subsequently <br /> fluorescence assay (IFA). Thin smears schizont-enriched P. falcipa-         determining proportion SYBR green I-positive cells. Samples were <br /> rum-infected erythrocytes prepared glass slides stored          tested triplicate experiment, independent experi- <br /> &#226;&#171;&#186;80&#194;&#176;C. The smears thawed, fixed 4% paraformaldehyde RT            ments performed. <br /> for 10 min, permeabilized PBS-T (PBS containing 0.1% Triton                   The human IgGs purified serum samples Mali also <br /> X-100) RT 15 min, blocked PBS containing 5% nonfat milk        tested parasite invasion growth-inhibitory activity cycle <br /> (blocking solution) 37&#194;&#176;C 30 min.                                        parasite replication GIA Reference Center, NIAID, NIH. The GIA <br />      Free merozoites isolated described above, added uninfected     reaction mixture incubated 40 h presence test IgG allow <br /> erythrocytes, processed invasion described previously (14).         invading parasites develop schizont stage, then <br /> Invading merozoites collected 2 10 min incubation        parasite growth determined biochemical assay specific para- <br /> erythrocytes shaker 37&#194;&#176;C, fixed RT 30 min 4% parafor-      site lactate dehydrogenase previously described (20). <br /> maldehyde&#226;&#8364;&#8220; 0.0075% glutaraldehyde PBS, permeabilized PBS-T              Immunoprecipitation. Immunoprecipitation carried pre- <br /> RT 15 min, blocked PBS containing 3% bovine serum albumin             viously described (17). Briefly, proteins extracted late schizont <br /> (BSA) 37&#194;&#176;C 30 min, applied polyethyleneimine-coated         parasite pellets PBS 1% Triton X-100 containing Complete pro- <br /> coverslips.                                                                    tease inhibitor. Fifty-microliter samples supernatants preincu- <br />      The antigen samples IFA described stained pri-        bated 4&#194;&#176;C 1 h 40 &#226;?&#174;l 50% protein G-conjugated beads (pro- <br /> mary antibodies diluted following concentrations blocking solu-      tein G-Sepharose 4 Fast Flow; GE Healthcare) NETT buffer (50 mM <br /> tion 37&#194;&#176;C 1 h: rabbit anti-RALP1-C1 antibody, 1:500; rabbit anti-       Tris-HCl, 0.15 M NaCl, 1 mM EDTA, 0.5% Triton X-100) supplemented <br /> RALP1-C2 antibody, 1:500; mouse anti-RALP1-N1 antibody, 1:100;                 0.5% BSA (fraction V; Sigma-Aldrich Corporation). Aliquots re- <br /> mouse anti-RAP1 antibody, 1:100 (17); mouse anti-RON4 monoclonal               covered supernatants incubated rabbit anti-RALP1-N1, anti- <br /> antibody, 1:1,000 (gift Jean F. Dubremetz). Secondary antibodies,         RALP1-C1, anti-AMA1, anti-GST antibody, 40 &#226;?&#174;l 50% <br /> Alexa Fluor 488-conjugated goat anti-rabbit IgG Alexa Fluor 568-           protein G-conjugated bead suspension added. After incubation 1 <br /> conjugated goat anti-mouse IgG (Invitrogen), used 1:500 dilu-        h 4&#194;&#176;C, beads washed NETT&#226;&#8364;&#8220; 0.5% BSA, with <br /> tion blocking solution 37&#194;&#176;C 30 min. DAPI (4=,6-diamidino-2-          NETT, high-salt (0.5 M NaCl) NETT, NETT, and <br /> phenylindole) 2 &#226;?&#174;g/ml added secondary-antibody              low-salt (0.05 M NaCl, 0.17% Triton X-100) NETT. Finally, <br /> solution stain nuclei. Slides mounted ProLong Gold Anti-        proteins extracted protein G-conjugated beads incuba- <br /> fade reagent (Invitrogen) viewed 63&#226;&#171;&#187; oil immersion lens.           tion 1&#226;&#171;&#187; SDS-PAGE reducing loading buffer 98&#194;&#176;C 3 min. The <br /> High-resolution image capture processing performed             supernatants used Western blot analysis. <br /> confocal scanning laser microscope (LSM710; Carl Zeiss MicroImaging,               FACS-based EBA. An assay checking erythrocyte-binding ac- <br /> Thornwood, NY). Images processed Adobe Photoshop (Adobe                tivity RALP1 basis protocol used assay the <br /> Systems Inc., San Jose, CA).                                                   erythrocyte-binding activity Duffy antigen (21). Rh5 P. falciparum is <br />      IEM. Parasites fixed embedded LR White resin (Poly-           unique erythrocyte-binding proteins de- <br /> sciences, Inc., Warrington, PA) previously described (18). Ultrathin        leted P. falciparum strain. Both native recombinant Rh5 <br /> sections immunostained previously described (19). Samples         previously shown bind erythrocytes (22). Therefore, used <br /> examined transmission electron microscope (JEM-1230; JEOL,              Rh5 universal positive-control protein erythrocyte-binding as- <br /> Tokyo, Japan).                                                                 say (EBA). In brief, GST-tagged RALP1-N2, RALP1-C1, full-<span id='am-4' about='xsp:length' typeof='owl:Thing'>length</span> Rh5 <br />      GIAs. Total rabbit IgGs growth inhibition assays (GIAs) pu-      (comprising aa E26 Q526 3D7 sequence [PF3D7_0424100] with- <br /> rified rabbit antisera HiTrap protein G-Sepharose columns (GE        signal peptide), GST (negative control) synthesized by <br /> Healthcare) according manufacturer&#226;&#8364;&#8482;s protocol. Purified IgGs       wheat germ cell-free purified glutathione-Sepharose <br /> further buffer exchanged incomplete culture medium, concentrated          column chromatography glutathione elution described above. <br /> with Amicon Ultra-15 centrifugal filter units (Millipore), filter sterilized   Erythrocytes washed times PBS&#226;&#8364;&#8220;1% BSA, resuspended to <br /> with Ultrafree-MC GV 0.22-&#226;?&#174;m centrifugal filter (Millipore), pre-       1 &#226;&#171;&#187; 105 cells 200 &#226;?&#174;l PBS&#226;&#8364;&#8220;1% BSA, preincubated 20 &#226;?&#174;g <br /> absorbed remove nonspecific antierythrocyte antibodies 25 &#226;?&#174;l        recombinant protein RT 3 h. After preincubation, erythrocytes were <br /> packed human O&#226;&#171;&#185; erythrocytes purified IgG 1 ml antiserum           washed PBS incubated fluorescein isothiocyanate <br /> at RT 1 h rotating wheel. Finally, concentrations rabbit   (FITC)-conjugated anti-GST antibody (1:100 PBS 1% BSA; Ab- <br /> IgG samples adjusted 40 mg/ml incomplete culture medium.            cam, Cambridge, United Kingdom) RT 1 h protected from <br />      The inhibitory activity rabbit IgGs merozoite invasion tested   light. Erythrocytes washed PBS once, resuspended 200 &#226;?&#174;l of <br /> over cycle parasite replication, parasitemia determined      PBS, transferred fluorescence-activated cell sorter (FACS) tubes. A <br />  <br />  <br /> 4292     iai.asm.org                                                                                                                   Infection Immunity <br />                                                                                                   P. falciparum RALP1, Potential Malaria Vaccine Candidate <br />  <br />  <br />  <br /> total 50,000 erythrocytes read FACSCanto II flow cytometer,      teins. The N1, C1, C2 truncated proteins used immu- <br /> and resulting flow cytometry data analyzed FlowJo software.     nize rabbits mice produce antibodies. <br /> The percentage erythrocytes bound recombinant RALP1 (%                 RALP1 expression analyzed RALP1-specific antibod- <br /> cells) obtained percentage erythrocytes positive       ies Western blot assay protein extracts synchronized <br /> FITC signal background FITC measurement erythrocytes             schizont-rich parasites. All antisera raised N1, <br /> without recombinant protein. <br />                                                                               C1, C2 truncated forms RALP1 recognized protein of <br />     IFA-based MIBA. Total IgGs tested merozoite invasion- <br /> blocking assay (MIBA) purified rabbit antisera described         &#226;&#172;&#381;90 kDa protein extracts P. falciparum parasites schi- <br /> above. To filtered merozoites, antibodies added final con-      zont stages (Fig. 1C, arrowhead), corresponding predicted <br /> centration 20 mg/ml total IgG anti-RALP1-C1 anti-GST serum        molecular mass 88 kDa. Additionally, anti-RALP1-N1 both <br /> (diluted incomplete culture medium) uninfected erythrocytes            anti-RALP1-C1 anti-RALP1-C2 antisera recognized distinct <br /> (50% hematocrit; 10 &#226;?&#174;l) incubated 37&#194;&#176;C 10 min. Control assays      53- 50-kDa proteins, respectively, represent processed N- <br /> were performed incomplete culture medium. After fixation             C-terminal forms RALP1 protein (Fig. 1C, asterisks). In <br /> washing, samples processed IFA DAPI mouse anti-             case anti-RALP1-C1 -C2 antiserum staining, faint <br /> RAP1 antibody described above. For condition, biological        band 40 kDa visible, suggesting processing <br /> replicates approximately 2,000 erythrocytes attached invading      event C-terminal region RALP1. The negative-control <br /> parasites scored confocal scanning laser microscope. <br />                                                                               lane stained secondary antibody showed signal <br />     ELISAs. Human serum samples western Thailand collected <br /> from asymptomatic P. falciparum carriers written informed consent        (Fig. 1C, Ctrl), indicating signals described were <br /> as previously described (23). The study approved Ethics Com-       specific. <br /> mittee Thai Ministry Public Health Institutional Review         In order confirm exact localization RALP1 mero- <br /> Board Walter Reed Army Institute Research (WRAIR number             zoite rhoptries, used antisera RAP1, rhoptry bulb <br /> 802) (23). Human serum samples collected adults living      marker, RON4, rhoptry neck marker, test RALP1 resides in <br /> the village Kenieroba, Mali (24). The study approved ethical    compartments IFA (Fig. 1D). The IFA results showed <br /> review committees Faculty Medicine, Pharmacy, Dentistry      apical distribution RALP1, detected anti-RALP1-C2 <br /> the University Bamako (Mali) NIAID, National Institutes         antiserum, clearly RON4 (Fig. 1D, middle) and <br /> Health, Bethesda, MD (NIAID protocol number 08-I-N120). Individual            RAP1 (Fig. 1D, top). Furthermore, distribution of <br /> written informed consent obtained participants. Measure- <br />                                                                               RALP1 detected anti-RALP1-C2 antiserum overlaps of <br /> ments antibodies recombinant RALP1-C1 1:1,000-di- <br /> luted Thai Mali sera performed previously described (24). The      RALP1 detected anti-RALP1-N1 antiserum (Fig. 1D, bottom). <br /> enzyme-linked immunosorbent assays (ELISAs) replicated twice in-         IFA anti-RALP1-C1 antiserum shows RALP1 colocal- <br /> dependently.                                                                  izes RON4 (see Fig. S1 supplemental material). <br />     Statistical analysis. The Mann-Whitney U test used test            To validate precise subcellular localization of <br /> significance differences ELISA values groups, Spear-        RALP1 merozoite electron microscopy, parasites late <br /> man&#226;&#8364;&#8482;s rank correlation test used test correlation ELISA    schizont stages stained RALP1-C2 specific IgG sub- <br /> and GIA values. For GIA EBA data, Kruskal-Wallis test used,       sequently secondary antibody labeled gold particles. <br /> followed Dunn&#226;&#8364;&#8482;s multiple-comparison test examine differences        Gold particle signals detected neck portion the <br /> between negative-control- experimental-group values. For MIBA,            rhoptries merozoites (Fig. 1E). Together, findings estab- <br /> Fisher&#226;&#8364;&#8482;s exact test Bonferroni correction performed. All statisti- <br />                                                                               lish RALP1 novel RON merozoites. <br /> cal analyses performed GraphPad Prism (GraphPad Software, <br /> San Diego, CA).                                                                   RALP1 translocates moving junction merozo- <br />                                                                               ite invasion. The data study (11) supporting direct <br /> RESULTS                                                                       role RALP1 parasite invasion limited. It clear our <br /> RALP1 localized merozoite rhoptry neck. In order                 data RALP1 expressed rhoptry neck merozoite <br /> characterize RALP1, produced recombinant RALP1 proteins                    antibodies inhibit merozoite invasion. Recent stud- <br /> (Fig. 1A codon optimization. Figure 1B shows differ-              ies shown RONs Rhs tight- <br /> ent truncated RALP1 proteins, RALP1-N1 (predicted molecular                   junction proteins, suggesting specific role RONs this <br /> mass, 13.9 kDa), RALP1-C1 (27.5 kDa), RALP1-N2 (fused                    invasion process (10, 25). To investigate role of <br /> GST, 76.0 kDa), RALP1-C2 (37.4 kDa), resolved 12.5%                  RALP1 merozoite invasion erythrocytes, performed <br /> SDS-polyacrylamide gel stained Coomassie brilliant blue              IFA analyzed localization RALP1 reference to <br /> R-250. N1, C1, C2 truncated versions RALP1 protein                 rhoptry neck bulb markers (RON4 RAP1), have <br /> were recovered supernatant fraction easily purified             shown previously localize tight junction PV, <br /> single dominant bands (Fig. 1B, arrowheads) affinity chroma-               respectively, merozoite invasion (26). By using invading <br /> tography. Since electrophoretic mobility N1, C1, C2            merozoites, showed confocal microscopic examination that <br /> proteins (Fig. 1B, arrowhead) slower, observed molecular             RALP1 colocalized RON4 moving junction through- <br /> masses higher predicted molecular masses. Even                 invasion process (Fig. 2A). Figure 2B shows RAP1 <br /> though RALP1-N2 derived multiple bands, full-length                  fluorescence seen surrounding parasite PV late <br /> band slightly faster electrophoretic mobility clearly seen           invasion stages. However, RALP1 fluorescence observed not <br /> (Fig. 1B, arrowhead). The appearance smaller bands N2 pro-              PV posterior end parasite (Fig. 2B). <br /> teins (Fig. 1B, asterisks) caused translational arrest          Taken together, observations indicate RALP1 tight- <br /> during reaction, smaller bands retain            junction protein suggest RALP1 play important <br /> GST tag N terminus (data shown). These results dem-                role merozoite invasion erythrocytes. <br /> onstrate wheat germ cell-free able translate            RALP1 does interact AMA1. To investigate whether <br /> native RALP1-encoding gene sequences produce soluble pro-                 RALP1 interacts well-known RON-AMA1 moving-junc- <br />  <br />  <br /> November 2013 Volume 81 Number 11                                                                                                        iai.asm.org 4293 <br />  Ito et al. <br />  <br />  <br />  <br />  <br />                                                                                    FIG 2 RALP1 localized moving junction invasion. RALP1 <br />                                                                                    colocalizes moving-junction marker (RON4) early through <br />                                                                                    mid late stages invasion (A). RAP1 used PV marker (B). Scale <br />                                                                                    bars represent 5 &#226;?&#174;m. DIC, differential interference contrast. <br />  <br />  <br />                                                                                    tion complex, performed coimmunoprecipitation experi- <br />                                                                                    ments anti-RALP1 anti-AMA1 antibodies mature- <br />                                                                                    schizont-rich parasite extracts. Immunoprecipitation either <br />                                                                                    anti-RALP1-N1 anti-RALP1-C1 antibodies, pull down <br />                                                                                    RALP1 schizont lysates, brought full-length <br />                                                                                    RALP1 protein (approximately 90 kDa) processed RALP1 <br />                                                                                    fragment (approximately 50 kDa) AMA1 RON4 (Fig. <br />                                                                                    3). The reciprocal experiment, immunoprecipitated <br />                                                                                    AMA1 anti-AMA1 antibody, pulled AMA1 <br />                                                                                    RON4 control RON-AMA1 complex not <br />                                                                                    RALP1. As negative control, proteins detected an <br />                                                                                    immunoprecipitation experiment anti-GST antibody <br />                                                                                    (Fig. 3). <br />                                                                                        RALP1 binds human erythrocytes C-terminal <br />                                                                                    region. Since RALP1 protein possesses coiled-coil do- <br />                                                                                    mains, including leucine zipper-like domain repre- <br />                                                                                    sent protein-protein interaction domain (Fig. 1A), local- <br /> FIG 1 Structure, expression, localization RALP1 P. falciparum mero- <br /> zoites. (A) Schematic primary structure RALP1. The RALP1 protein         ized moving junction (Fig. 2), investigated RALP1 <br /> consists 749 aa calculated molecular mass 87.9 kDa. The predicted     binds human erythrocytes. While preferable use native <br /> signal peptide (SP; residues 1 17), leucine zipper-like domain (LZ; residues    parasite RALP1 protein, Haase et al. (11) previously reported <br /> 511 532), coiled-coil domain (CC; residues 86 158 595 624)    RALP1 detectable parasite culture supernatants <br /> indicated. RALP1-N1 (residues 35 148), RALP1-N2 (residues 17 412), <br /> RALP1-C1 (residues 396 634), RALP1-C2 (residues 396 710) were <br />                                                                                    RALP1 appears partition insoluble fraction the <br /> expressed recombinant proteins, antibodies raised RALP1-       late-stage parasite lysate (more 50%), does not <br /> N1, RALP1-C1, RALP1-C2. (B) SDS-PAGE recombinant RALP1 pro-                 contain predicted transmembrane domain GPI anchor signal. <br /> teins. All recombinant RALP1 proteins synthesized wheat       Therefore, used recombinant GST-tagged RALP1 proteins for <br /> germ cell-free protein expression purified affinity purification <br /> columns. The fractions purified RALP1-N1 (predicted molecular mass, 13.9 <br /> kDa), RALP1-C1 (27.5 kDa), RALP1-N2 (fused GST, 76.0 kDa), and <br /> RALP1-C2 (37.4 kDa) proteins resolved 12.5% SDS-PAGE stained           probed rabbit anti-RALP1-C2 (green) mouse anti-RAP1 (rhop- <br /> Coomassie brilliant blue R-250 shown. Arrowheads indicate bands full-       try bulb marker) antibodies (top) anti-RON4 (rhoptry neck marker) (mid- <br /> length proteins. Asterisks represent bands truncated N2 proteins. (C) De-       dle) anti-RALP1-N1 (bottom) (red) antibody. Parasite nuclei stained <br /> tection RALP1 schizont lysate. Total schizont material examined       DAPI (blue). Scale bars represent 5 &#226;?&#174;m. DIC, differential interference <br /> Western blotting reducing condition rabbit anti-RALP1-N1 (&#226;?&#163;-            contrast. (E) RALP1 localization shown IEM. Two sections merozoites in <br /> N1), anti-RALP1-C1 (&#226;?&#163;-C1), anti-RALP1-C2 (&#226;?&#163;-C2) antisera. The arrow-           schizont-infected erythrocytes probed purified rabbit anti-RALP1-C2 <br /> head indicates full-length RALP1, asterisks indicate processed N-      antibody subsequently secondary antibody conjugated gold <br /> and C-terminal forms RALP1 protein. (D) RALP1 localization shown         particles shown. The black dots indicate signals gold particles local- <br /> an immunofluorescence assay. Paraformaldehyde-fixed mature schizonts               ized rhoptry necks. R, rhoptry. <br />  <br />  <br />  <br /> 4294     iai.asm.org                                                                                                                       Infection Immunity <br />                                                                                                          P. falciparum RALP1, Potential Malaria Vaccine Candidate <br />  <br />  <br />  <br />  <br />                                                                                   FIG 5 Anti-RALP1-C1 antibody invasion-inhibitory activity vitro. The <br />                                                                                   ability anti-RALP1-N1 (&#226;?&#163;-N1) anti-RALP1-C1 (&#226;?&#163;-C1) antibodies <br />                                                                                   inhibit parasite invasion erythrocytes tested one-cycle GIA. <br />                                                                                   Anti-AMA1 (&#226;?&#163;AMA1) anti-GST (&#226;?&#163;GST) antibodies used positive <br />                                                                                   negative controls, respectively. The error bars represent standard er- <br />                                                                                   rors means independent experiments. The Kruskal-Wallis test <br />                                                                                   performed, followed Dunn&#226;&#8364;&#8482;s multiple-comparison test, compare <br />                                                                                   percent inhibition anti-GST anti-RALP1-N1 antibodies anti-GST <br />                                                                                   anti-RALP1-C1 antibodies. ns, significant. <br /> FIG 3 RALP1 does interact RON-AMA1 complex. Triton X-100 <br /> extracts schizont-rich parasite (PfTx extract) immunoprecipitated (IP) <br /> with rabbit serum RALP1-N1, RALP1-C1, AMA1, GST then <br /> detected Western blotting (WB) mouse antiserum RALP1-N1,          unknown. Considering erythrocyte- <br /> RALP1-C1, AMA1, RON4. Immunoprecipitation anti-GST antibody               binding epitope middle region RALP1, designed <br /> was used negative control. No bands detected anti-GST im-        RALP1-N2, overlaps N terminus RALP1-C1 17 aa <br /> munoprecipitate.                                                                  residues (i.e., N396 Q412). The erythrocyte-binding activity of <br />                                                                                   RALP1-C1 (mean &#226;&#171;&#190; standard error mean [SEM], <br /> the EBA. The EBA performed glutathione affinity-puri-                    4.6% &#226;&#171;&#190; 0.7%) significantly higher negative <br /> fied, GST-tagged Rh5, RALP1-N2, RALP1-C1, GST (Fig. 4A).                      control, GST (2.3% &#226;&#171;&#190; 0.4%) (P &#226;&#172;? 0.05). The binding activity of <br /> As shown Fig. 1C, RALP1 undergoes processing cleavage                    RALP1-N2 similar GST (Fig. 4B). These results <br /> its middle portion; however, precise cleavage site RALP1                suggest RALP1 erythrocyte-binding epitope C- <br />                                                                                   terminal region RALP1 new erythrocyte-binding pro- <br />                                                                                   tein P. falciparum. <br />                                                                                       Antibodies RALP1-C1 inhibit merozoite invasion. In or- <br />                                                                                   der test antibodies RALP1 block parasite in- <br />                                                                                   vasion, rabbit polyclonal IgGs RALP1-N1 -C1 tested <br />                                                                                   inhibition parasite growth cycle replication with <br />                                                                                   measurement parasite growth flow cytometry. When anti- <br />                                                                                   RALP1-N1, anti-RALP1-C1, anti-AMA1 (positive control), and <br />                                                                                   anti-GST (negative control) antibodies tested final con- <br />                                                                                   centration 20 mg/ml (total IgG concentration), inhibited <br />                                                                                   invasion (mean &#226;&#171;&#190; SEM) 10% &#226;&#171;&#190; 0.8%, 39% &#226;&#171;&#190; 1.6%, 51% &#226;&#171;&#190; <br />                                                                                   0.9%, 7.8% &#226;&#171;&#190; 1.6%, respectively (Fig. 5). The invasion-inhib- <br />                                                                                   iting activity anti-RALP1-C1 antibody significantly higher <br />                                                                                   negative-control anti-GST antibody (P &#226;&#172;? 0.001). <br />                                                                                   Anti-RALP1-N1 antibody did significant inhibition ac- <br />                                                                                   tivity, inhibition activity negligible the <br /> FIG 4 EBA recombinant RALP1. (A) SDS-PAGE recombinant pro-                anti-GST antibody. <br /> teins used EBA. All recombinant proteins synthesized         Anti-RALP1 antibodies cause merozoites aberrantly re- <br /> wheat germ cell-free protein expression GST fusion proteins         lease RAP1 IFA-based MIBA. To understand about <br /> purified affinity purification columns. The fractions purified, GST- <br /> tagged Rh5 (87 kDa), GST (27 kDa), RALP1-N2 (76 kDa), RALP1-C1 (55            mechanism invasion inhibition anti-RALP1-C1 anti- <br /> kDa) proteins resolved SDS-PAGE stained Coomassie brilliant           body GIA, performed MIBA evaluates, IFA <br /> blue R-250 shown. (B) Erythrocyte-binding activities recombinant           inspection, efficiency isolated viable, invasion- <br /> RALP1 proteins. The GST-tagged recombinant proteins incubated           competent merozoites invade erythrocytes presence an- <br /> human erythrocytes. Then recombinant proteins bound erythrocytes <br />                                                                                   tibodies. In order count parasites invading erythrocytes to <br /> were stained FITC-conjugated anti-GST antibody. The labeled erythro- <br /> cytes counted flow cytometry. As control, erythrocytes absence   distinguish pre- postinvasion merozoites, IFA was <br /> of recombinant proteins counted flow cytometry (None). The       performed DAPI labeling nuclear marker RAP1 <br /> vertical axis represents mean percentage erythrocytes bound re-       labeling PV marker. Figure 6A shows different states of <br /> combinant protein calculated independent experiments. The error         RAP1 release merozoite invasion erythrocytes: state 1, <br /> bars indicate standard errors means independent experi- <br /> ments. The Kruskal-Wallis test performed, followed Dunn&#226;&#8364;&#8482;s multiple-        RAP1 unreleased (i.e., released); state 2, RAP1 properly <br /> comparison test, compare means GST RALP1-N2 groups           released PV; state 3, RAP1 aberrantly released the <br /> the GST anti-RALP1-C1 groups. ns, significant.                            erythrocyte merozoite surface. As untreated control, per- <br />  <br />  <br /> November 2013 Volume 81 Number 11                                                                                                               iai.asm.org 4295 <br />  Ito et al. <br />  <br />  <br />  <br />  <br /> FIG 6 Anti-RALP1 antibody causes merozoites aberrantly release RAP1 in <br /> a MIBA. (A) Imaging erythrocyte-associated merozoites stained anti- <br /> RAP1 antibody DAPI analysis RAP1 localization invasion in <br /> the presence anti-RALP1-C1 antibody. Merozoites categorized into <br /> three types based RAP1 staining patterns: 1, RAP1 unreleased; 2, RAP1 <br /> properly released PV; 3, RAP1 aberrantly released erythrocyte <br /> or merozoite surface. The scale bars represent 5 &#226;?&#174;m. DIC, differential inter- <br /> ference contrast. (B) Stacked bar graph comparing mean percentages         FIG 7 Human sera areas Thailand Mali malaria endemic <br /> merozoites types 1 3 (shown panel A) presence anti-GST         recognize RALP1 ELISA. Probing RALP1-C1 sera P. falci- <br /> (&#226;?&#163;GST) anti-RALP1-C1 (&#226;?&#163;-C1) antibody.                                          parum-infected asymptomatic Thai adults (Asymptomatic) naive, nonex- <br />                                                                                   posed Thai adults (Normal) (A) sera semi-immune adults in <br />                                                                                   Mali (Immune) naive, nonexposed U.S. adults (Normal) (B). P values <br /> formed MIBA incomplete culture medium                          calculated Mann-Whitney U test. The number (n) serum samples <br />                                                                                   analyzed shown. (C) Correlation anti-RAPL1-C1 antibody titers <br /> antibodies. There significant difference observed                  (logarithmic scale) vitro growth-inhibitory activities Mali semi- <br /> the total number merozoites associated untreated eryth-                   immune serum samples. The graph shows significant positive correlation <br /> rocytes associated erythrocytes treated                 antibody titers growth-inhibitory activities (Spearman&#226;&#8364;&#8482;s rank <br /> anti-GST antibody (mean &#226;&#171;&#190; SEM, 108% &#226;&#171;&#190; 5% untreated-                        correlation, r &#226;&#171;&#189; 0.51; 95% confidence interval, 0.14 0.75; P &#226;&#172;? 0.01). OD, <br />                                                                                   optical density; dil., dilution. <br /> control value) anti-RALP1-C1 antibody (112% &#226;&#171;&#190; 5%). Fur- <br /> thermore, proportion parasites unreleased RAP1 (Fig. <br /> 6A, state 1) observed presence anti-RALP1-C1 (&#226;?&#163;-C1)                     Sera asymptomatic Thai adults (asymptomatic) showed signif- <br /> antibody significantly different (Fisher&#226;&#8364;&#8482;s exact test ad-                 icantly higher reactivity RALP1-C1 malaria-naive <br /> justed P &#226;&#171;&#189; 0.48) observed presence anti-GST                      Thai individuals (normal) (P &#226;&#172;? 0.01, Mann-Whitney U test) (Fig. <br /> (&#226;?&#163;GST) antibody (Fig. 6B, state 1).                                               7A), sera semi-immune adults Mali (Immune) <br />     However, proportion merozoites invaded (Fig.                  showed significantly higher reactivity RALP1-C1 of <br /> 6A, state 2) (measured counting properly secreted RAP1 stain-                  malaria-naive U.S. adults (normal) (P &#226;&#172;? 0.01, Mann-Whitney U <br /> ing) significantly reduced anti-RALP1-C1 antibody com-                     test) (Fig. 7B). We evaluated functional activity purified <br /> pared anti-GST antibody (Fisher&#226;&#8364;&#8482;s exact test adjusted P &#226;&#172;?                      IgGs Malian sera P. falciparum 3D7 parasites in <br /> 0.001) (Fig. 6B, state 2). Importantly, proportion merozo-                 vitro GIA investigate correlation antibody titer <br /> ites released RAP1 aberrantly (Fig. 6A, state 3) signifi-                RAPL1-C1 vitro growth-inhibitory activity. As <br /> cantly higher presence anti-RALP1-C1 antibody                   shown Fig. 7C, significant positive correlation be- <br /> the presence control anti-GST antibody (Fisher&#226;&#8364;&#8482;s exact test ad-                tween antibody titer growth-inhibitory activity (Spearman&#226;&#8364;&#8482;s <br /> justed P &#226;&#172;? 0.001) (Fig. 6B, state 3). Samples tested tripli-              rank correlation, r &#226;&#171;&#189; 0.51; 95% confidence interval, 0.14 0.75; <br /> cate experiment. Two independent experiments                         P &#226;&#172;? 0.01). Taken together, results suggest RALP1 is <br /> were performed (see Fig. S2 supplemental material),                    immunogenic malaria infection humans. <br /> these results agreement Fig. 6B. In short, these <br /> results suggest anti-RALP1 antibody affects merozoite inva-                  DISCUSSION <br /> sion erythrocytes merozoite attachment erythro-                     RALP1 P. falciparum previously specifically <br /> cytes.                                                                            expressed schizont stages localized rhoptry mero- <br />     Reactivity RALP1 human immune sera. Since anti-                         zoites basis IFA. It refractory gene <br /> RALP1 antibodies inhibited merozoite invasion vitro (Fig. 5                knockout attempts, suggesting RALP1 essential blood- <br /> 6B), decided investigate RALP1 exposed                    stage parasite survival; however, RAPL1 experimen- <br /> human immune P. falciparum-infected individuals                     tally characterized vaccine candidate. Here, aimed char- <br /> generates immune response. In order test presence                acterize RALP1 P. falciparum blood-stage vaccine candidate <br /> anti-RALP1 antibody sera, tested sera P. falci-                    using recombinant RALP1 expressed wheat germ cell- <br /> parum-infected asymptomatic adults western Thailand na-                    free system. <br /> ive, nonexposed Thai adults antibodies RALP1-C1 recom-                         Our Western blotting results (Fig. 1C) agreement with <br /> binant protein ELISA (Fig. 7A) sera semi-immune                       previous report (11) primary processing events occur in <br /> adults Mali, western Africa, naive, nonexposed U.S.                   RALP1. In addition, IEM results (Fig. 1E) confirmed for <br /> adults antibodies RALP1-C1 recombinant protein (Fig. 7B).                  time RALP1 localized merozoite <br />  <br />  <br /> 4296     iai.asm.org                                                                                                                      Infection Immunity <br />                                                                                                  P. falciparum RALP1, Potential Malaria Vaccine Candidate <br />  <br />  <br />  <br /> rhoptry neck, hence, RALP1 represents novel RON. Fur-               reside outside leucine zipper-like domain (residues 511 532 <br /> thermore, IFA results obtained merozoites invading               Fig. 1A) coiled-coil domain (residues 595 624 Fig. 1A) <br /> erythrocytes (Fig. 2) revealed RALP1 translocates mov-        RALP1. These preliminary SNP analyses suggest leu- <br /> ing junction invasion RALP1 novel tight-            cine zipper-like domain coiled-coil domain RAPL1 are <br /> junction protein. Since RALP1 tight-junction protein, ex-         essential function protein. However, validate this <br /> pected RALP1 component RON-AMA1                    claim, need analysis SNPs RALP1 different field <br /> complex. However, immunoprecipitation results showed             isolates worldwide. <br /> neither AMA1 RON4 immunoprecipitated                        Overall, findings indicate RALP1 novel rhoptry <br /> RALP1, suggesting RALP1 RON-AMA1                  neck erythrocyte-binding blood-stage antigen P. falciparum <br /> complex (Fig. 3). The fact RALP1 novel tight-junction           merozoites, immunogenic antigen humans that <br /> protein (Fig. 2) erythrocyte-binding epitope C-ter-        target antibodies contribute acquired immu- <br /> minal region (Fig. 4) suggests RALP1 plays role bridging      nity falciparum malaria. Therefore, RALP1 potential <br /> protein erythrocyte surface merozoite sur-            blood-stage vaccine candidate antigen P. falciparum. This study <br /> face. However, lack transmembrane region RALP1 (Fig.          substantiates claims wheat germ cell-free system <br /> 1A) suggests RALP1 associated unknown               valuable tool identification novel malaria vaccine <br /> membrane protein anchored merozoite surface               candidates. <br /> RALP1 plays role invasion ligand, Rh proteins <br /> (10, 27). Therefore, studies required RALP1       ACKNOWLEDGMENTS <br /> receptor erythrocyte membrane possible merozoite               We grateful adults Kenieroba, Mali, donated sera, and <br /> surface proteins anchor RALP1 parasite surface.               appreciate efforts Rick Fairhurst, Mahamadou Diakite, Jennifer <br />     GIA MIBA measure capacity antibodies limit              Anderson, Saibou Doumbia facilitating availability sera. <br /> parasite growth and/or invasion P. falciparum vitro (28). Our       We grateful Jean F. Dubremetz anti-RON4 monoclonal <br /> GIA MIBA results anti-RALP1 antibodies specifi-             antibody. We thank Masachika Shudo, Integrated Center Science, <br /> cally inhibited invasion erythrocytes merozoites        Ehime University, Japan technical assistance. We thank Japa- <br /> the attachment merozoites erythrocytes. Our MIBA results            nese Red Cross Society providing human erythrocytes human <br />                                                                           plasma. <br /> clearly anti-RALP1 antibody caused merozoites to <br />                                                                               This work supported MEXT KAKENHI (23117008) and <br /> aberrantly release RAP1 merozoite erythrocyte surface         JSPS KAKENHI (23406007) Japan grant Ministry of <br /> and host cell negative control did, suggesting      Health, Labor, Welfare (H21-Chikyukibo-ippan-005), Japan. The <br /> that RALP1 plays important role correct tight-junction for-         study Malian samples supported intramural program of <br /> mation normal release RAP1 host cell. The             NIAID, NIH, PATH Malaria Vaccine Initiative. <br /> aberrant RAP1 release observed study akin previ- <br /> ously described abortive merozoite invasion anomalous              REFERENCES <br /> premature rhoptry bulb release merozoite invasion            1. WHO. 2011. World malaria report 2011. WHO Press, Geneva, Switzer- <br /> presence R1 inhibitory peptide blocks formation            land. <br />                                                                            2. Crompton PD, Pierce SK, Miller LH. 2010. Advances challenges in <br /> the RON-AMA1 complex (26). Our data consistent the <br />                                                                               malaria vaccine development. J. Clin. Invest. 120:4168 &#226;&#8364;&#8220; 4178. <br /> previous finding (26) rhoptry bulb release correct tight-         3. Greenwood BM, Targett GA. 2011. Malaria vaccines new malaria <br /> junction formation occur independently triggered                 agenda. Clin. Microbiol. Infect. 17:1600 &#226;&#8364;&#8220;1607. <br /> after committed merozoite attachment&#226;&#8364;&#8221;an event likely initiated             4. Birkett AJ. 2010. PATH Malaria Vaccine Initiative (MVI): perspectives on <br /> by erythrocyte-binding-like/Rh proteins (26).                                 status malaria vaccine development. Hum. Vaccin. 6:139 &#226;&#8364;&#8220;145. <br />                                                                            5. Cowman AF, Crabb BS. 2006. Invasion red blood cells malaria <br />     Immunoreactive antigens involved erythrocyte invasion                  parasites. Cell 124:755&#226;&#8364;&#8220;766. <br /> represent potential candidates malaria vaccine (29), de-           6. Iyer J, Gruner AC, Renia L, Snounou G, Preiser PR. 2007. Invasion of <br /> signing vaccine based sequences immunoreactive antigens               host cells malaria parasites: tale protein families. Mol. Micro- <br /> with minimum polymorphisms critical preventing para-                biol. 65:231&#226;&#8364;&#8220;249. <br />                                                                            7. Preiser P, Kaviratne M, Khan S, Bannister L, Jarra W. 2000. The apical <br /> site evading vaccine-induced immunity. Not our <br />                                                                               organelles malaria merozoites: host cell selection, invasion, host immu- <br /> GIA results (Fig. 5) indicate antibodies RALP1-C1                nity immune evasion. Microbes Infect. 2:1461&#226;&#8364;&#8220;1477. <br /> have invasion-inhibitory activity, immunoscreening re-             8. Alexander DL, Arastu-Kapur S, Dubremetz JF, Boothroyd JC. 2006. <br /> sults (Fig. 7) demonstrate significant correlation       Plasmodium falciparum AMA1 binds rhoptry neck protein homologous <br /> between reactivity Mali semi-immune sera                   TgRON4, component moving junction Toxoplasma gondii. <br />                                                                               Eukaryot. Cell 5:1169 &#226;&#8364;&#8220;1173. <br /> RAPL1-C1 vitro growth-inhibitory activity, suggesting          9. Cao J, Kaneko O, Thongkukiatkul A, Tachibana M, Otsuki H, Gao Q, <br /> RALP1-C1 contains invasion-inhibitory epitope corre-                  Tsuboi T, Torii M. 2009. Rhoptry neck protein RON2 forms complex <br /> lates immunity humans developed following natural in-                 microneme protein AMA1 Plasmodium falciparum merozoites. <br /> fection areas malaria endemic.                                    Parasitol. Int. 58:29 &#226;&#8364;&#8220;35. <br />                                                                           10. Gunalan K, Gao X, Yap SS, Huang X, Preiser PR. 2013. The role the <br />     Previous preliminary single nucleotide polymorphism (SNP) <br />                                                                       <br /> </body></html>